Protalix BioTherapeutics, Inc. Common Stock (PLX)

Price$1.99

Value ScoreB

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)3.87%

Price vs S&P 500 (4W)2.59%

VGM Score60.69

Market Capitalization$160.34M

P/E Ratio (Annual)63.20x

All Metrics

P/CF (Annual)21.36x

Book Value / Share (Quarterly)$0.83

Revenue Growth (3Y)3.45%

Cash Flow / Share (Quarterly)$0.16

Price vs S&P 500 (YTD)2.40%

Gross Margin (TTM)69.97%

Net Profit Margin (TTM)20.07%

EPS (TTM)$0.18

10-Day Avg Trading Volume0.71M

EPS Excl Extra (TTM)$0.18

Revenue Growth (5Y)-3.46%

EPS (Annual)$-0.08

ROI (Annual)-13.69%

Gross Margin (Annual)48.82%

Net Profit Margin (5Y Avg)-19.52%

Cash / Share (Quarterly)$0.63

P/E Basic Excl Extra (TTM)10.46x

Revenue Growth QoQ (YoY)233.73%

P/E Normalized (Annual)63.20x

ROA (Last FY)-8.02%

Revenue Growth TTM (YoY)27.80%

EBITD / Share (TTM)$0.26

ROE (5Y Avg)70.52%

Operating Margin (TTM)25.91%

Cash Flow / Share (Annual)$-0.17

P/B Ratio2.38x

P/B Ratio (Quarterly)2.60x

Net Income / Employee (Annual)$-29,200

EV / Revenue (TTM)1.56x

Net Interest Coverage (TTM)-50.93x

ROA (TTM)17.75%

EPS Growth QoQ (YoY)-26.88%

EV / EBITDA (TTM)5.60x

EPS Incl Extra (Annual)$-0.08

Current Ratio (Annual)2.51x

Quick Ratio (Quarterly)2.04x

3-Month Avg Trading Volume1.10M

52-Week Price Return30.92%

EV / Free Cash Flow (Annual)23.22x

P/E Incl Extra (TTM)10.46x

Revenue / Employee (TTM)$338,000

Tangible BV / Share (Quarterly)$0.52

P/S Ratio (Annual)3.04x

Asset Turnover (Annual)0.64x

52-Week High$3.19

Operating Margin (5Y Avg)-13.56%

EPS Excl Extra (Annual)$-0.08

CapEx CAGR (5Y)19.94%

26-Week Price Return11.80%

Quick Ratio (Annual)1.53x

13-Week Price Return-28.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.15x

Enterprise Value$119.34M

Revenue / Share Growth (5Y)-20.82%

Asset Turnover (TTM)0.88x

Revenue / Employee (Annual)$233,400

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)-10.63%

Cash / Share (Annual)$0.38

3-Month Return Std Dev60.00%

Gross Margin (5Y Avg)56.89%

Net Income / Employee (TTM)$67,800

ROE (Last FY)-13.69%

Net Interest Coverage (Annual)27.85x

EPS Basic Excl Extra (Annual)$-0.08

P/FCF (TTM)7.00x

Receivables Turnover (TTM)20.06x

EV / Free Cash Flow (TTM)9.18x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.18

Receivables Turnover (Annual)8.98x

ROI (TTM)28.10%

P/S Ratio (TTM)2.10x

Pretax Margin (5Y Avg)-18.38%

Revenue / Share (Annual)$0.67

Tangible BV / Share (Annual)$-0.20

Forward P/E10.21x

Price vs S&P 500 (52W)6.56%

P/E Ratio (TTM)10.46x

EPS Growth TTM (YoY)638.87%

Year-to-Date Return10.56%

5-Day Price Return-3.40%

EPS Normalized (Annual)$-0.08

ROA (5Y Avg)-11.67%

Net Profit Margin (Annual)-12.52%

Month-to-Date Return-5.69%

Cash Flow / Share (TTM)$0.18

EBITD / Share (Annual)$-0.05

Operating Margin (Annual)-10.43%

LT Debt / Equity (Annual)6.61x

P/CF (TTM)10.63x

ROI (5Y Avg)-23.85%

P/E Excl Extra (TTM)10.46x

LT Debt / Equity (Quarterly)0.52x

EPS Basic Excl Extra (TTM)$0.18

P/TBV (Quarterly)2.73x

P/B Ratio (Annual)3.00x

Inventory Turnover (TTM)0.92x

Pretax Margin (TTM)25.22%

Book Value / Share (Annual)$0.60

Price vs S&P 500 (13W)-36.67%

Beta0.05x

P/FCF (Annual)21.69x

Revenue / Share (TTM)$0.92

ROE (TTM)28.10%

52-Week Low$1.32

vGradeB

gGradeB

mGradeC

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.22est. -0.01

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
PLXProtalix BioTherapeutics, Inc. Common Stock	B	B	C	$1.99
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Protalix BioTherapeutics develops recombinant therapeutic proteins using its proprietary ProCellEx platform to treat rare lysosomal storage and genetic diseases, including Gaucher disease, Fabry disease, and cystic fibrosis. Revenue comes from product sales in Brazil and a manufacturing supply agreement with Pfizer. The company's pipeline includes ELFABRIO, Uricase, and Long Acting DNase I.